Home Belantamab mafodotin detection by MASS-FIX and immunofixation
Article
Licensed
Unlicensed Requires Authentication

Belantamab mafodotin detection by MASS-FIX and immunofixation

  • Patrick W. Mellors ORCID logo , Mindy C. Kohlhagen , Surendra Dasari , Maria A. V. Willrich , Morie A. Gertz , Shaji K. Kumar , Martha Q. Lacy , David L. Murray and Angela Dispenzieri ORCID logo EMAIL logo
Published/Copyright: June 11, 2021

Received: 2021-03-17
Accepted: 2021-05-28
Published Online: 2021-06-11
Published in Print: 2021-10-26

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Drone transport of biological samples: an open issue
  4. Review
  5. Pre-analytical considerations in biomarker research: focus on cardiovascular disease
  6. Opinion Papers
  7. Diagnostic algorithms for non-ST-segment elevation myocardial infarction: open issues
  8. The effect of drone transport on the stability of biochemical, coagulation and hematological parameters in healthy individuals
  9. General Clinical Chemistry and Laboratory Medicine
  10. Notification of biochemistry critical results and its clinical impact on outpatient care: experience in a Spanish tertiary hospital
  11. The utility of competency-oriented clinical laboratory teaching combined with case-based learning (CBL)
  12. Vitamin D retesting by general practitioners: a factor and cost analysis
  13. Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies
  14. Quantitative profiling of inflammatory and pro-resolving lipid mediators in human adolescents and mouse plasma using UHPLC-MS/MS
  15. Urine organic acids may be useful biomarkers for metabolic syndrome and its components in Korean adults
  16. A morphological classification of the fat particles found in the urinary sediment of patients with Fabry disease
  17. Reference Values and Biological Variations
  18. Distribution of HOMA-IR in a population-based cohort and proposal for reference intervals
  19. A screening method to spot biomarkers that may warn of serious events in a chronic disease – illustrated by cardiological CLARICOR trial data
  20. Cancer Diagnostics
  21. Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma
  22. The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers
  23. Infectious Diseases
  24. Serological diagnostic for SARS-CoV-2: an experimental External Quality Assessment Scheme
  25. Letters to the Editor
  26. The high frequency of anti-PF4/heparin antibodies in patients with COVID-19 is neither related to heparin treatment or to an increased incidence of thrombosis
  27. Is COVID-19 a hyperferritinemic syndrome in children?
  28. Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients
  29. Does COVID-19 alter the oxyhemoglobin dissociation curve? – An observational cohort study using a mixed-effect modelling
  30. Low serum TSH in the acute phase of COVID-19 pneumonia: thyrotoxicosis or a face of “non-thyroidal illness syndrome”?
  31. False-positive pregnancy test: beware of familial hCG syndrome
  32. A protein standard addition method for absolute quantification of cystatin C in human serum by LC-MS/MS
  33. The clinical significance of the peritoneal dialysis evaluation test in the Department of Laboratory Medicine
  34. Belantamab mafodotin detection by MASS-FIX and immunofixation
Downloaded on 9.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2021-0326/html
Scroll to top button